Completed PHASE2 INTERVENTIONAL 4-arm NCT00584974

A Safety, Efficacy and Tolerability Study of SEP-225289

A Double-Blind, Placebo-Controlled Study Examining The Safety, Efficacy, and Tolerability of SEP-225289 in Subjects With Major Depressive Disorder (Including Atypical and Melancholic Features)

Sponsor: Sumitomo Pharma America, Inc.

Conditions Depressive Disorder, Major

Interventions SEP-225289 Venlafaxine placebo

Updated 9 times since 2017 Last updated: Feb 21, 2012 Started: Dec 31, 2007 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Depressive Disorder, Major, this trial is completed. The trial is conducted by Sumitomo Pharma America, Inc. and has accumulated 9 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2023 — Jul 2024 [monthly]

Completed PHASE2
Apr 2022 — Sep 2023 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sumitomo Pharma America, Inc.

Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Arcadia, United States , Atlanta, United States , Austin, United States , Beverly Hills, United States , Boston, United States , Bradenton, United States , Braintree, United States , Brooklyn, United States , Cincinnati, United States and 36 more locations